1. Home
  2. AR vs HALO Comparison

AR vs HALO Comparison

Compare AR & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Antero Resources Corporation

AR

Antero Resources Corporation

HOLD

Current Price

$37.39

Market Cap

10.8B

Sector

Energy

ML Signal

HOLD

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

HOLD

Current Price

$108.64

Market Cap

11.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AR
HALO
Founded
2002
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.8B
11.2B
IPO Year
2013
2001

Fundamental Metrics

Financial Performance
Metric
AR
HALO
Price
$37.39
$108.64
Analyst Decision
Buy
Buy
Analyst Count
16
11
Target Price
$47.13
$78.64
AVG Volume (30 Days)
4.2M
2.3M
Earning Date
04-29-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
1027.78
N/A
EPS
2.62
3.11
Revenue
$5,275,823,000.00
$151,862,000.00
Revenue This Year
$29.74
$28.24
Revenue Next Year
$5.07
$12.56
P/E Ratio
$14.47
$34.93
Revenue Growth
21.97
N/A
52 Week Low
$29.10
$61.23
52 Week High
$45.75
$109.10

Technical Indicators

Market Signals
Indicator
AR
HALO
Relative Strength Index (RSI) 57.99 78.09
Support Level $32.82 $62.63
Resistance Level $37.93 N/A
Average True Range (ATR) 0.95 3.62
MACD 0.10 0.59
Stochastic Oscillator 76.96 95.74

Price Performance

Historical Comparison
AR
HALO

About AR Antero Resources Corporation

Antero Resources is an exploration and production firm whose operations represent a pure play in the Marcellus Shale, located in northern West Virginia. The company started in 2002 as an E&P focused on the Barnett Shale (Fort Worth, Texas). Antero redefined itself in Appalachia's Marcellus Shale in 2005. In 2012, shortly before Antero's 2013 IPO, Antero Midstream Partners was formed to handle the company's rapidly growing gas volumes. In 2026, the firm narrowed its focus further by selling its Ohio Utica assets and using the proceeds to acquire additional Marcellus acreage from HG Energy. Just over half of its production and earning power is tied to natural gas, with the remainder mostly NGLs, where it holds a leading position, and some crude oil.

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Share on Social Networks: